View in EDS

Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types.

Saved in:
Bibliographic Details
Title: Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types.
Authors: Oh J; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Korea., Hwa C; School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, 02841, Korea.; BK21FOUR R&E Center for Learning Health Systems, Korea University, Seoul, 02841, Korea.; Department of Integrated Biomedical and Life Science, Korea University, Seoul, 02841, Korea., Jang D; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Shin S; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Lee SJ; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Kim J; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Lee SE; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea., Jung HR; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Oh Y; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Jang G; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., Kwon O; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea.; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea., An JY; School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, 02841, Korea. joonan30@korea.ac.kr.; BK21FOUR R&E Center for Learning Health Systems, Korea University, Seoul, 02841, Korea. joonan30@korea.ac.kr., Cho SY; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Korea. csybio@snu.ac.kr.; Cancer Research Institute, Seoul National University, Seoul, 03080, Korea. csybio@snu.ac.kr.
Source: Experimental & molecular medicine [Exp Mol Med] 2022 Jul; Vol. 54 (7), pp. 906-921. Date of Electronic Publication: 2022 Jul 06.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9607880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2092-6413 (Electronic) Linking ISSN: 12263613 NLM ISO Abbreviation: Exp Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2092-6413
DOI:10.1038/s12276-022-00795-z